7. Comerica is a diversified bank operating in Michigan, California, Texas and Florida. Second-quarter profit nearly quadrupled to $70 million, or 39 cents a share, beating the consensus estimate by 70%. Revenue declined 22%, but the operating margin extended to 32% from 14%.
Comerica shares sell for a forward earnings multiple of 17, a modest discount to the financial services industry average. Of analysts covering the stock, 11, or 38%, rank it "buy," 14 rate it "hold" and four rate it "sell." A median target of $43.14 suggests 9% of upside remains.
6. Advanced Micro Devices makes semiconductors for computing and graphics markets. The company's second-quarter loss narrowed to $43 million, or 6 cents a share, from a loss of $310 million, or 49 cents, a year earlier. The earnings-per-share tally exceeded expectations by 75%. Advanced Micro's shares have rallied 9% since the announcement. They trade at a forward earnings multiple of 11 and a cash flow multiple of 5.8 -- 20% and 67% discounts to industry averages. Roughly 28% of analysts covering Advanced Micro Devices rate its stock "buy."
5. Citigroup is a diversified financial-services company. Second-quarter net income fell 37% to $2.7 billion and earnings per share tumbled 82% to 9 cents, still exceeding analysts' consensus estimate by a margin of 84%. Quarterly revenue grew 11% and the operating margin climbed into positive territory. Citigroup shares have gained 1% since the quarterly report. They sell for a price-to-projected-earnings ratio of 9.2 and a price-to-book ratio of 0.8 -- 34% and 11% discounts to peer averages. Of researchers covering the stock, 13, or 52%, rate it "buy."
4. Boston Scientific makes medical equipment, including cardiovascular and endosurgery devices. Second-quarter profit decreased 38% to $98 million, or 6 cents a share, surpassing analysts' consensus estimate by 87%. The operating margin narrowed to 13% from 17%. Boston Scientific has declined 3% since the release. It trades at a book-value multiple of 0.8 and a sales multiple of 1.1 — 80% and 72% discounts to health-care-equipment industry averages. Of firms evaluating Boston Scientific, eight, or 18%, advocate buying its shares.